Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: A retrospective study

Therapeutic Advances in Psychopharmacology

Volumn 2, Issue 6, 2012, Pages 217-226

  Eriksson, Lars ^a   Hallerbäck, Teresa ^b   Jørgensen, Leif ^b   Carlborg, Andreas ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Comorbidity; concomitant medication; in patients; naturalistic study; quetiapine; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DRUG DOSE COMPARISON; DRUG RELEASE; EXTENDED DRUG RELEASE; FEMALE; HOSPITAL PATIENT; HUMAN; IMMEDIATE DRUG RELEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOPHRENIA; SOMATOFORM DISORDER; SUBSTANCE ABUSE; TREATMENT OUTCOME;

EID: 84998183105     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312453935     Document Type: Article

References (44)

1. Altamura A. Armadoros D. Jaeger M. Kernish R. Locklear J. Volz HP. (2008) Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. Curr Med Res Opin 8: 2271–2282.
2. Altamura A. Glick I. (2010) Designing outcome studies to determine efficacy and safety of antipsychotics for ‘real world’ treatment of schizophrenia. Int J Neuropsychopharmacol 13: 971–973.
3. Andrews G. (1999) Randomized controlled trials in psychiatry: important but poorly accepted. BMJ 319: 562–564.
4. Ascher-Svanum H. Nyhuis A.W. Stauffer V. Kinon B.J. Faries D.E. Phillips G.A. et al. (2010) Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin 10: 2403–2410.
5. Baldwin C. Scott L. (2009) Quetiapine extended release: in schizophrenia. CNS Drugs 23: 261–269.
6. Barnes T. Paton C. (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25: 383–399.
7. Bingefors K. Isacson D. Lindstrom E. (2003) Dosage patterns of antipsychotic drugs for the treatment of schizophrenia in Swedish ambulatory clinical practise – a highly individualised therapy. Nord J Psychiatry 57: 263–269.
8. Broekema W. de Groot I.W. van Harten P.N. (2007) Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics – a European study. Pharm World Sci 29: 126–130.
9. Buchanan R. Kreyenbuhl J. Deanna L.K. Jason M.N. Douglas L.B. Bernard A.F. et al. (2010) Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 1: 71–93.
10. Carlborg A. Winnerback K. Jonsson E.G. Jokinen J. Nordstrom P. (2010) Suicide in schizophrenia. Expert Rev Neurother 10: 1153–1164.
11. Datto C. Berggren L. Patel J.B. Eriksson H. (2009) Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 31: 492–502.
12. Diaz E. Neuse E. Sullivan M.C. Pearsall H.R. Woods S.W. (2004) Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 65: 354–360.
13. Figueroa C. Brecherb M. Jennifer E. Hamer M. Winterb H. (2009) Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 33: 199–204.
14. Fleishhacker W. Hofer A. Hummer M. (2007) Managing Schizophrenia: The Compliance Challenge, second edition. London: Current Medicine Group.
15. Gardner D. Baldessarini R. Waraich P. (2005) Modern antipsychotic drugs: a critical overview. Can Med Assoc J 172: 1703–1711.
16. Geddes J. (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 231: 1371–1376.
17. Goff D.C. Hill M. Freudenreich O. (2011) Treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 72: e13.
18. Gorwood P. (2006) Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol 16: 156–162.
19. Hansson L. (2006) Determinants of quality of life in people with severe mental illness. Acta Psychiatr Scand 429: 46–50.
20. Hardeman S.M. Harding R.K. Narasimhan M. (2010) Simplifying adherence in schizophrenia. Psychiatr Serv 61: 405–408.
21. Johnsen E. Kroken R.A. Wentzel-Larsen T. J⊘rgensen H.A. (2010) Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 10: 26–38.
22. Kane J. Correll C. (2010) Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci 12: 345–357.
23. Kapur S. Zipursky R. Jones C. Shammi C.S. Remington G. Seeman P. (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57: 553–559.
24. Kroken R.A. Johnsen E. Ruud T. Wentzel-Larsen T. J⊘rgensen H.A. (2009) Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 9: 24–33.
25. Laan W. Does Y. Sezgi B. Smeets H.M. Stolker J.J. Wit N.J. Heerdink E.R. (2010) Low treatment adherence with antipsychotics is associated with relapse in psychotic disorders within six months after discharge. Pharmacopsychiatry 43: 221–224.
26. Leucht S. Heres S. (2006) Epidemiology, clinical consequences, and psychosocial treatment of non-adherence in schizophrenia. J Clin Psychiatry 67: 3–8.
27. Llorca P. (2008) Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 161: 235–247.
28. Mamo D.C. Uchida H. Vitcu I. Barsoum P. Gendron A. Goldstein J. et al. (2008) Quetiapine extended-release versus immediate release formulation: a positron emission tomography study. J Clin Psychiatry 69: 81–86.
29. McCue R.E. Waheed R. Urcuyo L. Orendain G. Joseph M.D. Charles R. et al. (2006) Comparative effectiveness of second-generation antipsychotic and haloperidol in acute schizophrenia. Br J Psychiatry 189: 433–440.
30. Meulien D. Huizar K. Brecher M. (2010) Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol 25: 103–115.
31. Mulholland C. Cooper S. (2000) The symptom of depression in schizophrenia and its management. Adv Psychiatr Treat 6: 169–177.
32. Naber D. Lambert M. (2009) The CATIE and CUtLASS studies in schizophrenia. CNS Drugs 23: 649–659.
33. NICE (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance. London: National Institute for Health and Clinical Excellence.
34. Nord M. Nyberg S. Brogren J. Jucaite A. Halldin C. Farde L. (2011) Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol 14: 1357–1366.
35. Nyhuis A.W. Faries D.E. Ascher-Svanum H. Stauffer V.L. Kinon B.J. (2010) Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry 10: 75–86.
36. Parks J. Radke A. Parker G. Foti M.E. Eilers R. Diamond M. et al. (2009) Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull 35: 931–936.
37. Peuskens J. Trivedi J. Malyarov S. Brecher M. Svensson O. Miller F. et al. (2007) Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont) 4: 34–50.
38. Philip N.S. Mello K. Carpenter L.L. Tyrka A.R. Price L.H. (2008) Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry 20: 15–20.
39. Remington G. Kwon J. Collins A. Laporte D. Mann S. Christensen B. (2007) The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 90: 229–237.
40. Riedel M. Müller N. Strassnig M. Spellmann I. Severus E. Möller H-J. (2007) Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychchiatr Dis Treat 3: 219–235.
41. Simes R. (2002) Clinical trials and ‘real world’ medicine. MJA 177: 407–408.
42. Tapp A. Wood A.E. Secrest L. Erdmann J. Cubberley L. Kilzieh N. (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54: 55–59.
43. Thieda P. Beard S. Richter A. Kane J. (2003) An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 54: 508–516.
44. Wolff-Menzler C. Hasan A. Malchow B. Falkai P. Wobrock T. (2010) Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry 43: 122–129.